1. Scrip
  2. >>Business
  3. >>Strategy

Best of the Blog: START-UP ( August 2008)

 
• By Ellen Licking, Mark Ratner, and Tom Salemi

Three of the top blog posts from August 2008: Proteostasis Proves Platform Companies Still in Vogue; Covidien Ventures Out; TauRx's Alzheimer's Drug: A Web of Tangles.

Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In August Windhover’s editorial staff posted 28 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory, and commercial news. Here are a few of our favorite blog posts for stories not covered elsewhere in this month’s START-UP.

(August 26.) It pays to be fashionable. Anyone doubting that platform-based, big think biotech start-ups have gone by the wayside should think again. On [August 25] Proteostasis Therapeutics Inc....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.